Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: A Markov model

American Journal of Cardiovascular Drugs

Volumn 8, Issue 6, 2008, Pages 419-427

  Ara, Roberta ^a   Pandor, Abdullah ^a   Tumur, Indra ^a   Paisley, Suzy ^a   Duenas, Alejandra ^a   Williams, Robert ^a   Rees, Angie ^a   Wilkinson, Anna ^a   Durrington, Paul ^b   Chilcott, Jim ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiovascular disorders, treatment; Cholesterol absorption inhibitors, therapeutic use; Cost analysis; Drug tolerance; Ezetimibe, therapeutic use

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG USE; HEART INFARCTION; HUMAN; META ANALYSIS; MONEY; MONOTHERAPY; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PARAMETER; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL SIGNIFICANCE; STROKE; SYSTEMATIC REVIEW;

AGE FACTORS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS;

EID: 59449103939     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/0129784-200808060-00005     Document Type: Article

References (49)

1. Allender S, Peto V, Scarborough P, et al. Coronary heart disease statistics 2006 edition. Oxford: British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford, 2006
2. Peterson S, Peto V, Rayner M, et al. A European cardiovascular disease statistics 2005 edition. Oxford: British Heart Foundation, 2005
3. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 Suppl. 5: V1-V52
4. Primatesta P, Poulter NR. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf) 2006; 64 (3): 292-8
5. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct 8; 366 (9493): 1267-78
6. NHS Centre for Reviews and Dissemination. Cholesterol and coronary heart disease: screening and treatment. Effective Health Care Bull 1998; 4 (1): 1-16
7. Husereau DR. Ezetimibe for lowering blood cholesterol. Issues Emerg Health Technol 2003; (49): 1-4
8. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007 Sep; 194 (1): 1-45
9. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24 (8): e149-61
10. Ara R, Tumur I, Pandor A, et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess 2008 May; 12 (21): iii, xi-xiii, 1-212
11. Health & Social Care Information Centre prescription cost analysis 2005 [online]. Available from URL: http://www.ic.nhs.uk/pubs/ prescostanalysis2005 [Accessed 2006 Oct 9]
12. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
13. Canner P, Furberg C, Terrin M, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005; 95: 254-7
14. Keech A, Simes R, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61
15. National Institute for Health and Clinical Excellence (NICE). NICE technology appraisal guidance 132: ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/guidance/TA132/ guidance/pdf/English [Accessed 2007 Oct 23]
16. Ward S, Lloyd-Jones M, Pandor A, et al. Statins for the prevention of cardiovascular events: an analysis of the clinical and cost effectiveness of statins in patients with, or at risk from, coronary heart disease (CHD). Health Technol Assess 2007; 11 (14): 1-340
17. Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. Med Decision Making 1993; 13: 322-39
18. British National Formulary [online]. Available from URL: http://www.bnf.org/bnf/ [Accessed 2006 Oct]
19. Gray D, Hampton J. Twenty years' experience of myocardial infarction: the value of a heart attack register. Nottingham Heart Attack Register. Br J Clin Pharmacol 1993; 47: 292-5
20. Wolfe CDA, Rudd AG, Howard R, et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry 2002; 72: 211-6
21. Palmer S, Sculpher M, Philips Z, et al. A cost-effectiveness model comparing alternative management strategies for the use of glycoprotein IIb/IIIa antagonists in non-ST-elevation acute coronary syndrome. Report to the National Institute for Clinical Excellence. London: NICE, 2002 [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Sep]
22. Youman P, Wilson K, Harraf F, et al. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003; Suppl. 1: 43-50
23. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20 (6): 442-50
24. Lenzen M, Scholte op Reimer W, Norekval T, et al. Pharmacological treatment and perceived health status during 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization. Results from the Euro Heart Survey on Coronary Revascularization. Eur J Cardiovasc Nurs 2006; 5: 115-21
25. BARI Investigators. Protocol for the Bypass Angioplasty Revascularization Investigation. Circulation 1991; 84 Suppl. 6: 1-27
26. Kim J, Henderson R, Pocock SJ, et al. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one year results of the third randomized intervention trial of unstable angina (RITA-3). J Am Coll Cardiol 2007; 45: 221-8
27. Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 2004; 328: 254-7
28. Lacey EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Commun Health 2003; 57: 622-7
29. Van Exel N, Scholte op Reimer W, Koopmanschap MA. Assessment of post-stroke quality of life in cost-effectiveness studies: the usefulness of the Barthel Index and the EuroQol-5D. Qual Life Res 2004; 13: 427-33
30. Leeds L, Meara J, Hobson P. The impact of discharge to a care home on longer term stroke outcomes. Clin Rehabil 2004; 18: 924-8
31. Pickard AS, Johnson JA, Feeny DH. Responsiveness of generic health-related quality of life measures in stroke. Qual Life Res 2005; 14: 207-19
32. Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-41
33. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal [reference NO515; online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Sep]
34. Kind. P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316 (7133): 736-41
35. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002 Nov 15; 90 (10): 1092-7
36. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107 (19): 2409-15
37. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003 Apr; 24 (8): 729-41
38. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003 Apr; 24 (8): 717-28
39. Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004 Nov; 26 (11): 1758-73
40. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40 (12): 2125-34
41. Goldberg AC, Sapre A, Liu J, et al., Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004 May; 79 (5): 620-9
42. Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics 2004; 22 Suppl. 3: 49-61
43. Kohli M, Attard C, Lam A, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics 2006; 24 (8): 815-30
44. Durrington PN. Hyperlipidaemia: diagnosis and management. 3rd ed. London: Hodder Arnold, 2007
45. Brown M, Goldstein J. Lowering LDL-not only how low, but how long? Science 2006; 311: 1721-3
46. Buchwald H, Varco R, Matts J, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolaemia. Report of the Program on the Surgical Control of Hyperlipidaemia (POSCH). N Engl J Med 1990; 323: 946-55
47. Birjmohus R, Hutten B, Kastelein JP, et al. Efficacy and safety of high-density lipoprotein cholesterol -increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-97
48. Lenzer J. Unreported cholesterol drug data released by company. BMJ 2008; 336: 180-1
49. Public advisory: Health Canada endorsed important safety information on Ezetrol® (ezetimibe). Health Canada, 2005 Feb [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/medeff/ ezetrol-hpc-cps-eng.pdf [Accessed 2008 Feb 14]